63rd Endocrine Society of Australia Annual Scientific Meeting 2020

Keeping pace with the dynamic world in managing adult patients with type 2 diabetes (72315)

Jonathan Shaw 1
  1. Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia

About 2 in 3 Australian adults with type 2 diabetes (T2D) also have cardiovascular disease (CVD) and/or chronic kidney disease (CKD).1,2 Indeed, CVD accounts for almost 1 in 3 deaths for people with T2D, and overall life expectancy is shortened by up to 8–9 years.1 This burden of disease highlights the importance of selecting glucose-lowering therapies that minimise the risk of cardiovascular events. Additionally, recent updates to the ADA/EASD consensus statement emphasise the need to manage CV risks in patients with T2D.3

Join Professor Jonathan Shaw as he explains the recent guideline changes and the main findings of key cardiovascular outcomes trials in patients with T2D. The discussion will include key consideration for clinical practice when needing to minimise the risk of CV events in patients with T2D.

  1. Shaw JE, Thomas M, Magliano D. The dark heart of type 2 diabetes. Baker Heart and Diabetes Institute, 2018. Available at https://www.baker.edu.au/-/media/documents/impact/Baker-Institute-The-dark-heart-of-type-2-diabetes.ashx?la=en. Accessed 1 October, 2020.
  2. International Diabetes Federation. IDF Diabetes Atlas. 9th ed. 2019.
  3. Buse JB et al. Diabetes Care 2020;43:487–93